LearnGlossaryMarketStocksSuperinvestorsSign in

PYXS

Pyxis Oncology, Inc.

Healthcare · $184M market cap

Verdict

We can't put a fair value on PYXS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-39.8% a year✗
Sales growth-14.2% a year✗
Free cash flow growth—?
Return on invested capital-61.8%✗

Follow PYXS

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 4, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Civik Thomas

CEO & Chairman of the Board · 2026-09-04

Award

$9.7M

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works